1 active not recruiting, 1 completed, 1 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Ashutosh Kumar Tewari: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance Poly-ICLC intramuscular (IM) injection, Poly-ICLC, Intertumoral (IT) injection - Prostate Cancer Patients on Active Surveillance | Phase 2 | Recruiting | Ashutosh Kumar Tewari | 114 | 2024-01-16 | 2024-04-02 |
| The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting. PGV-001, Poly-ICLC, CDX-301 - Prostate Cancer | Phase 1 | Active not recruiting | Ashutosh Kumar Tewari | 27 | 2022-01-05 | 2026-01-07 |
| Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM) Poly ICLC - Prostate Cancer | Phase 1 | Completed | Ashutosh Kumar Tewari | 13 | 2017-06-16 | 2022-09-10 |
poly ICLC (3) · Injections (1) · Injections, Intramuscular (1)
United States (3)
Sujit S Nair, Ph.D. (2) · Ashutosh K. Tewari, MD (1) · Ashutosh Tewari, MD (1) · Dara Lundon, MD MSc MBA PhD (1) · Dimple Chakravarty, PhD (1) · Sujit S Nair, PhD (1)